Evariste Molimbou

Dr. Evariste Molimbou

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 December 2022 in Viruses
Verified
Journal Article
Open access
PDF file
ESEzechiel Ngoufack Jagni Semengue
Ezechiel Ngoufack Jagni Semengue
JFJoseph Fokam
Joseph Fokam
NENaomi-Karell Etame
Naomi-Karell Etame
Evariste MolimbouEvariste Molimbou
Evariste Molimbou
CACollins Chenwi Ambe
Collins Chenwi Ambe
ANAlexis Ndjolo
Alexis Ndjolo
To ensure optimal prescribing practices in the dolutegravir-era in Cameroon, we compared first-line virological response (VR) under tenofovir + lamivudine + dolutegravir (TLD) according to prior exposure to tenofovir + lamivudine + efavirenz (TLE). A facility-based survey was conducted among patients initiating antiretroviral therapy (ART) with TLD (I-TLD) versus those transitioning from TLE to TLD (T-TLD). HIV viral load was performed and unsuppressed participants (VL > 1000 copies/mL) had genotyping performed by Sanger sequencing. Of the 12,093 patients followed, 310 (mean-age: 41 ± 11 years; 52.26% female) complied with study criteria (171 I-TLD vs. 139 T-TLD). The median ART-duration was 14 (12–17) months among I-TLDs versus 28 (24.5–31) months among T-TLDs (15 (11–19) on TLE and 14 (9–15) on TLD), and 83.15% (148/178) were at WHO clinical stages I/II. The viral suppression rate (<1000 copies/mL) was 96.45%, with 97.08% among I-TLDs versus 95.68% among T-TLDs (p = 0.55). VR was similar in I-TLD versus T-TLD at 0.05). Genotyping was successful for 72.7% (8/11), with no major mutations to integrase inhibitors found. VR is optimal under first-line TLD after 14 months, even among TLE-exposed, thus confirming the effectiveness of transitioning from TLE to TLD in similar settings, supported by strong pharmacological potency and genetic barrier of dolutegravir.

19 January 2026 in Molecules
Verified
Journal Article
Open access
PDF file
VSValeria Stefanizzi
Valeria Stefanizzi
antonella minutoloantonella minutolo
antonella minutolo
Evariste MolimbouEvariste Molimbou
Evariste Molimbou
EBEmanuela Balestrieri
Emanuela Balestrieri
MGMartina Giudice
Martina Giudice
FMFrancesca Marino-Merlo
Francesca Marino-Merlo
Among the metal-derived complexes, recently, tin derivatives have been investigated as promising anti-cancer drug candidates. Our previous study showed that the tin-based compound Bu3SnOCOCF3 (TBT) exerts cytotoxic activity on solid tumor cell lines. In the present study, the effects of TBT were evaluated in vitro on HTLV-1-infected human lymphocytic cell lines at different stages of viral transformation, consisting of IL-2-dependent (PB2/IL-2) and IL-2-independent (PB2/NO-IL-2) cells, generated in our laboratory by HTLV-1 in vitro infection of lymphocytes from the same donor, and the C91/PL cell line established by co-cultivation with T cells from a patient with HTLV-1-positive leukemia. TBT induced a reliable and reproducible dose-dependent inhibition of metabolic activity and viability in the HTLV-1-infected cells. The effect was cell-type-dependent, with C91/PL cells being quite resistant. An investigation into the cytotoxic effects induced by TBT in HTLV-1-infected cells and data on caspase inhibitors/caspase activation indicated that apoptotic cell death was involved, but also that the possible involvement of other forms of cell death could not be excluded. Taken together, the results show for the first time that the tin-based compound, although not devoid of a certain cytotoxicity toward uninfected cells, can induce typical and potent effects on HTLV-1-infected cells.

1 January 2026 in Journal of Public Health in Africa
Verified
Journal Article
Open access
PDF file
MTMichel Carlos TOMMO TCHOUAKET
Michel Carlos TOMMO TCHOUAKET
JFJoseph Fokam
Joseph Fokam
ESEzechiel Ngoufack Jagni Semengue
Ezechiel Ngoufack Jagni Semengue
YBYagai Bouba
Yagai Bouba
CACollins Chenwi Ambe
Collins Chenwi Ambe
ANAlexis Ndjolo
Alexis Ndjolo
Background: Nasopharyngeal swabs (NASO) cause discomfort for patients, which can discourage them from getting tested for COVID-19 and limit case detection. It is therefore necessary to consider an alternative, more comfortable swab. Aim: Evaluated the concordance between nasopharyngeal and oropharyngeal sampling for COVID-19 diagnosis in the Cameroonian context. Setting: This study was carried out at “Chantal Biya” International Reference Centre for Research on HIV/AIDS Prevention and Management (CIRCB) in Yaoundé, Cameroon. Methods: A comparative study was conducted in April 2021 among consenting participants tested for COVID-19 at “Chantal Biya” International Reference Centre for Research on HIV/AIDS Prevention and Management (CIRCB) in Yaoundé, Cameroon. Sampling began with nasopharyngeal swabs, followed by oropharyngeal swabs, all taken by the same technician, and analysis was carried out using polymerase chain reaction (PCR) tests on the Abbott platform. Statistical analyses were performed using GraphPad version 6.0; p < 0.05 was considered statistically significant. Results: A total of 154 participants were enrolled (59.7% male, median age 38 years, interquartile range [IQR]: 30–49). Following PCR testing, the overall COVID-19 positivity rate was 36.36% (56/154), with 34.41% (n = 53/154) in nasopharyngeal versus 16.23% (n = 25/154) in oropharyngeal samples, p < 0.0002. The overall concordance rate was 78% (n = 120/154), with 39.28% positive concordance and 74.24% negative concordance (kappa = 0.441 [0.289–0.513]). According to severe acute respiratory syndrome coronavirus 2 viral load, the positive concordance was improved with high viral load (cycle threshold [CT]: ≤ 25): 61% (n = 11/18) versus 31% (n = 11/35) with low viral load (CT > 25), p = 0.037; odds ratio (OR) = 3.43. According to gender, the positive concordance was higher in men, 55% (n = 16/29), versus 25% (n = 6/24) in women, p = 0.021; OR = 0.27. Using nasopharyngeal swab as the gold standard, oropharyngeal swab had a sensitivity of 41.50% (n = 22/53), specificity 97.02% (n = 98/101), positive predictive value (PPV) 88% (n = 22/25) and negative predictive value (NPV) 76% (n = 98/129). Conclusion: Our evidence suggests a superiority effect of nasopharyngeal in detecting cases of COVID-19. However, the overall high PPV of oropharyngeal swab, and its improved performance with high viral load. Contribution: Therefore, in case of counter-indication to nasopharyngeal swabbing, oropharyngeal can be an acceptable alternative.

26 January 2026 in Diagnostic Microbiology and Infectious Disease
Verified
Journal Article
Closed access
JFJoseph Fokam
Joseph Fokam
NENaomi-Karell Etame
Naomi-Karell Etame
ESEzechiel Ngoufack Jagni Semengue
Ezechiel Ngoufack Jagni Semengue
CACollins Chenwi Ambe
Collins Chenwi Ambe
SISeth C. Inzaule
Seth C. Inzaule
ANAlexis Ndjolo
Alexis Ndjolo

Verified
Journal Article
Open access
PDF file
VSValeria Stefanizzi
Valeria Stefanizzi
Evariste MolimbouEvariste Molimbou
Evariste Molimbou
EBEmanuela Balestrieri
Emanuela Balestrieri
antonella minutoloantonella minutolo
antonella minutolo
FCFranca Maria Cordero
Franca Maria Cordero
FMFrancesca Marino-Merlo
Francesca Marino-Merlo
Human T-Lymphotropic virus type 1 (HTLV-1) lifelong infects at least 5–10 million people worldwide, a minority of whom develop severe lethal diseases including adult T-cell Leukemia/lymphoma and HTLV-1-associated myelopathy or tropical spastic paraparesis. Currently, no vaccines or curative therapies to fight HTLV-1 infection or diseases are available. Recently we found that a tributyltin molecule, Bu3SnOCOCF3 (TBT), which is more potent than cisplatin in inducing cytotoxic effects towards a panel of cell lines including high-tumorigenic cells, also exerted potent cytotoxic effects even towards HTLV-1-infected cell lines, mimicking different states of virus-driven transformation. The type of cell death involved was elusive. In the present study, the effects of TBT on virological and cell death parameters were investigated in HTLV-1-infected immortalized lymphocytes generated by in vitro infection and rendered with or without progressive independence from interleukin-2 as a growth factor. Molecular studies demonstrated that TBT affected HTLV-1 viral gene expression, especially HBZ. TBT confirmed its high cytotoxic potential on the HTLV-1-infected cell lines assayed, especially towards the IL-2-independent HTLV-1-infected cells. Investigation of mechanisms involved in cell death induced by TBT in HTLV-1-infected cells confirmed that caspase 3 and 8 activation, as well as apoptotic response, were relevant. In addition, pyroptosis as well as other unspecifed forms of lytic death presumably contribute to cell death induced by TBT in HTLV-1-infected cells, while a concomitant activation of an autophagic response by this compound seems to mitigate it. Overall, these experimental results outline a particular profile of TBT-induced cell death in HTLV-1-infected cells that is useful for future studies aimed at verifying the real potential of tin-based compounds to contrast diseases caused by HTLV-1.

1 January 2025 in Journal of Public Health in Africa
Verified
Journal Article
Open access
PDF file
JFJoseph Fokam
Joseph Fokam
CACyrille Alain Abega Abega
Cyrille Alain Abega Abega
ESEzechiel Ngoufack Jagni Semengue
Ezechiel Ngoufack Jagni Semengue
AAAissatou Abba
Aissatou Abba
DTDésiré Takou
Désiré Takou
ANAlexis Ndjolo
Alexis Ndjolo
Optimised supplies management for an efficient response in a context of a pandemic in Cameroon. Background: Response strategy against COVID-19 relies on adequate materials and consumables supply. Aim: As a national reference COVID-19 laboratory in Cameroon, the Chantal BIYA International Reference Center (CIRCB) has evaluated the consumption of materials and consumables supply for PCR, variant screening and sequencing, in view of better prediction of the needs. Setting: Chantal Biya International Reference Centre for research on human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS) prevention and management (CIRCB), Yaoundé-Cameroon. Methods: This was a descriptive cross-sectional study conducted between August 2021 and July 2022 which focused on stock supply evaluation through analysis of data from services performed at CIRCB, Cameroon. The weighted averages method was used in statistics. Results: Overall, 31 453 samples were received, 37 008 extractions and 37 248 PCRs were performed for COVID-19 diagnosis, representing an average monthly consumption of 3084 extractions and 3104 PCRs for ~2621 samples/month (~1.17 extractions/sample and ~1.18 PCRs/sample). Of the 2238 (7.1%) positive cases diagnosed, 265 were processed for variants’ screening and 200 to sequencing due to their high cycle threshold (CT < 25). In screening, 288 tests were used, i.e. 1.08 tests/sample. For sequencing, 279 tests were used, i.e. 1.39 tests/sample. Conclusion: The estimates obtained reveal a precise quantification of the supplies used for diagnosis, variant screening and sequencing during a season of high COVID-19 epidemics at CIRCB-Cameroon. Contribution: Adequate implementation of this logistical strategy would optimize supply management and help to save associated costs while ensuring effective genomic surveillance or response when faced with any public health incident in Cameroon.